NORML Pushes Back on Federal Rescheduling, Demands Full Cannabis Removal
Cannabis advocacy group argues federal rescheduling efforts inadequate, calls for complete descheduling instead of moving marijuana to lower schedule.
The National Organization for the Reform of Marijuana Laws (NORML) continues pushing federal lawmakers to pursue complete cannabis descheduling rather than settling for rescheduling proposals currently circulating in Washington. The advocacy group argues that moving cannabis from Schedule I to a lower controlled substance classification fails to address fundamental legal and regulatory barriers facing the industry.
NORML's position centers on the argument that any form of federal scheduling maintains cannabis under the Controlled Substances Act, preserving significant operational constraints for state-legal businesses. Even Schedule III classification would subject cannabis companies to continued federal oversight through the Drug Enforcement Administration and Food and Drug Administration, potentially creating new compliance burdens that could offset tax benefits from eliminating Section 280E restrictions.
The debate reflects broader industry divisions over regulatory strategy as cannabis companies weigh immediate relief against long-term policy goals. Many publicly traded cannabis operators, including major multi-state operators like Curaleaf Holdings (CURA) and Green Thumb Industries (GTII), have expressed support for rescheduling as a pragmatic first step that could provide immediate tax relief and banking access improvements.
However, NORML's descheduling advocacy aligns with concerns that partial federal reform could create a two-tiered system favoring large pharmaceutical companies over existing cannabis businesses. Complete removal from controlled substance scheduling would treat cannabis similarly to alcohol and tobacco, allowing states to maintain primary regulatory authority while eliminating federal criminal penalties.
The timing of NORML's renewed descheduling push comes as the Biden administration faces pressure to deliver on cannabis reform promises ahead of the 2024 election cycle. While rescheduling appears more politically feasible in the near term, advocacy groups continue pressing for comprehensive reform that would fully legitimize the estimated $25 billion legal cannabis market and provide clearer pathways for interstate commerce and institutional investment.